Upgrade to SI Premium - Free Trial

Alnylam Pharma (ALNY)

266.99 -4.38 (1.61%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

Alnylam Pharmaceuticals (ALNY) PT Lowered to $400 at JPMorgan July 22, 2026 7:21 AM - StreetInsider Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results July 16, 2026 8:00 AM - BizWire Alnylam advances Alzheimer's drug trials, reports mivelsiran safety data July 15, 2026 5:50 AM - StreetInsider Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease July 15, 2026 3:30 AM - BizWire Alnylam Pharmaceuticals (ALNY) Reiterated at Buy by Stifel Post CARDIO-TTRansform Failure July 14, 2026 7:29 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright July 14, 2026 6:54 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at BofA Securities July 14, 2026 6:02 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at Truist Securities July 13, 2026 7:08 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Raised to $400 at Morgan Stanley July 10, 2026 8:09 AM - StreetInsider Increasing unusual call volume: ACI LEVI IHI FE KHC BBIO IONS OCUL XME DOMO ALNY July 9, 2026 10:33 AM - StreetInsider Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile' July 9, 2026 6:16 AM - StreetInsider Canaccord Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) June 30, 2026 6:51 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $470 at H.C. Wainwright June 29, 2026 7:06 AM - StreetInsider Komodo Health expands AI platform deal with Alnylam June 25, 2026 9:00 AM - StreetInsider Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform June 25, 2026 9:00 AM - BizWire Alnylam to Host Tenth “RNAi Roundtable” Webcast Series June 12, 2026 9:00 AM - BizWire GENESIS Pharma expands Alnylam partnership to Nordic markets June 10, 2026 7:47 AM - StreetInsider GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region June 10, 2026 7:47 AM - BizWire H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) June 5, 2026 8:17 AM - StreetInsider Alnylam partners with Inceptive in $2B AI collaboration for drug discovery June 3, 2026 4:45 PM - StreetInsider Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics June 3, 2026 4:45 PM - BizWire Form 4 ALNYLAM PHARMACEUTICALS, For: Jun 01 Filed by: PYOTT DAVID E I June 3, 2026 4:25 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: Jun 01 Filed by: Cravatt Benjamin June 3, 2026 4:24 PM - SEC Filing Form 3 ALNYLAM PHARMACEUTICALS, For: Jun 01 Filed by: Cravatt Benjamin June 3, 2026 4:21 PM - SEC Filing Form 144 ALNYLAM PHARMACEUTICALS, Filed by: PYOTT DAVID E I June 1, 2026 4:25 PM - SEC Filing JPMorgan says large-cap biotech is back as profits and pipelines fuel upside May 28, 2026 4:07 PM - StreetInsider Form 8-K ALNYLAM PHARMACEUTICALS, For: May 20 May 27, 2026 4:31 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: Sigal Charles Elliott May 22, 2026 4:21 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: SCHULMAN AMY W May 22, 2026 4:19 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: Reitan Colleen F May 22, 2026 4:17 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: PYOTT DAVID E I May 22, 2026 4:15 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: KELLOGG PETER N May 22, 2026 4:13 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: HAMBURG MARGARET A May 22, 2026 4:11 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: BRANDICOURT OLIVIER May 22, 2026 4:09 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: Ausiello Dennis A May 22, 2026 4:07 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: May 20 Filed by: Arbuckle Stuart A May 22, 2026 4:05 PM - SEC Filing JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms May 20, 2026 3:10 PM - StreetInsider JPMorgan Reinstates Alnylam Pharmaceuticals (ALNY) at Overweight May 20, 2026 4:30 AM - StreetInsider Alnylam Issues 2025 Corporate Responsibility Report May 19, 2026 8:30 AM - BizWire Citi Starts Alnylam Pharmaceuticals (ALNY) at Buy May 18, 2026 4:14 PM - StreetInsider Form 4 ALNYLAM PHARMACEUTICALS, For: May 13 Filed by: SCHULMAN AMY W May 14, 2026 4:18 PM - SEC Filing Form SCHEDULE 13G/A ALNYLAM PHARMACEUTICALS, Filed by: Capital World Investors May 14, 2026 1:56 PM - SEC Filing Form SCHEDULE 13G/A ALNYLAM PHARMACEUTICALS, Filed by: Capital Research Global Investors May 14, 2026 10:20 AM - SEC Filing Alnylam presents vutrisiran data showing benefits across ATTR-CM patients May 12, 2026 5:27 AM - StreetInsider New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patien May 12, 2026 2:30 AM - BizWire Alnylam to Webcast Presentations at Upcoming Investor Conferences May 7, 2026 8:00 AM - BizWire Form SCHEDULE 13G/A ALNYLAM PHARMACEUTICALS, Filed by: FMR LLC May 6, 2026 11:01 AM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) May 5, 2026 7:29 AM - StreetInsider Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM May 4, 2026 8:30 AM - BizWire Alnylam Pharmaceuticals (ALNY) PT Lowered to $447 at Bernstein SocGen Group May 1, 2026 9:52 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Raised to $370 at Morgan Stanley May 1, 2026 9:13 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Raised to $377 at Wells Fargo May 1, 2026 7:53 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $445 at RBC Capital May 1, 2026 6:36 AM - StreetInsider Form 10-Q ALNYLAM PHARMACEUTICALS, For: Mar 31 April 30, 2026 8:21 AM - SEC Filing Form 8-K ALNYLAM PHARMACEUTICALS, For: Apr 30 April 30, 2026 8:08 AM - SEC Filing Alnylam Pharma (ALNY) Tops Q1 EPS by 108c, provides guidance April 30, 2026 8:02 AM - StreetInsider Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress April 30, 2026 8:00 AM - BizWire Form SCHEDULE 13G ALNYLAM PHARMACEUTICALS, Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 29, 2026 4:45 PM - SEC Filing U.S. Biotech stocks: Q1 earnings previews April 26, 2026 8:00 PM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $448 at Bernstein SocGen April 24, 2026 8:34 AM - StreetInsider Full Article List